Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

Executive Summary

Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.

Advertisement

Related Content

New EU Speedy Review Hopefuls: Novimmune, AveXis, bluebird bio, and Loxo Oncology
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Finance Watch: VC Interest Lags At Early Stage – 'Hogwash' Or Evidence-Based?
Keeping Track: We're Back!
IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose
Finance Watch: Happy Holidays For Flagship With A New $618m Fund
Rubius Prepares Off-The-Shelf Red Cell Therapies For First Human Trial In 2018
Provention Builds On J&J Disease Interception Model
Finance Watch: Former GSK CEO Witty, R&D Head Slaoui Join VC Firms
Liquidia Technologies Inc.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel